skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Radiotherapy Treatment Plans With RapidArc for Prostate Cancer Involving Seminal Vesicles and Lymph Nodes

Abstract

Purpose: Dosimetric results and treatment delivery efficiency of RapidArc plans to those of conventional intensity-modulated radiotherapy (IMRT) plans were compared using the Eclipse treatment planning system for high-risk prostate cancer. Materials and Methods: This study included 10 patients. The primary planning target volume (PTV{sub P}) contained prostate, seminal vesicles, and pelvic lymph nodes with a margin. The boost PTV (PTV{sub B}) contained prostate and seminal vesicles with a margin. The total prescription dose was 75.6 Gy (46.8 Gy to PTV{sub P} and an additional 28.8 Gy to PTV{sub B}; 1.8 Gy/fraction). Three plans were generated for each PTV: Multiple-field IMRT, one-arc RapidArc (1ARC), and two-arc RapidArc (2ARC). Results: In the primary IMRT with PTV{sub P}, average mean doses to bladder, rectum and small bowel were lower by 5.9%, 7.7% and 4.3%, respectively, than in the primary 1ARC and by 3.6%, 4.8% and 3.1%, respectively, than in the primary 2ARC. In the boost IMRT with PTV{sub B}, average mean doses to bladder and rectum were lower by 2.6% and 4.8% than with the boost 1ARC and were higher by 0.6% and 0.2% than with the boost 2ARC. Integral doses were 7% to 9% higher with RapidArc than with IMRT for bothmore » primary and boost plans. Treatment delivery time was reduced by 2-7 minutes using RapidArc. Conclusion: For PTVs including prostate, seminal vesicles, and lymph nodes, IMRT performed better in dose sparing for bladder, rectum, and small bowel than did RapidArc. For PTVs including prostate and seminal vesicles, RapidArc with two arcs provided plans comparable to those for IMRT. The treatment delivery is more efficient with RapidArc.« less

Authors:
 [1]; ; ;  [1]
  1. Department of Radiation Oncology, Duke University Medical Center, Durham, NC (United States)
Publication Date:
OSTI Identifier:
21372121
Resource Type:
Journal Article
Resource Relation:
Journal Name: International Journal of Radiation Oncology, Biology and Physics; Journal Volume: 76; Journal Issue: 3; Other Information: DOI: 10.1016/j.ijrobp.2009.07.1677; PII: S0360-3016(09)02718-7; Copyright (c) 2010 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved.
Country of Publication:
United States
Language:
English
Subject:
62 RADIOLOGY AND NUCLEAR MEDICINE; BLADDER; DELIVERY; INTEGRAL DOSES; LYMPH NODES; NEOPLASMS; PLANNING; PROSTATE; RADIOTHERAPY; RECTUM; BODY; DIGESTIVE SYSTEM; DISEASES; DOSES; GASTROINTESTINAL TRACT; GLANDS; INTESTINES; LARGE INTESTINE; LYMPHATIC SYSTEM; MALE GENITALS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIATION DOSES; RADIOLOGY; THERAPY; URINARY TRACT

Citation Formats

Yoo, Sua, E-mail: sua.yoo@duke.ed, Wu, Q. Jackie, Lee, W. Robert, and Yin Fangfang. Radiotherapy Treatment Plans With RapidArc for Prostate Cancer Involving Seminal Vesicles and Lymph Nodes. United States: N. p., 2010. Web. doi:10.1016/j.ijrobp.2009.07.1677.
Yoo, Sua, E-mail: sua.yoo@duke.ed, Wu, Q. Jackie, Lee, W. Robert, & Yin Fangfang. Radiotherapy Treatment Plans With RapidArc for Prostate Cancer Involving Seminal Vesicles and Lymph Nodes. United States. doi:10.1016/j.ijrobp.2009.07.1677.
Yoo, Sua, E-mail: sua.yoo@duke.ed, Wu, Q. Jackie, Lee, W. Robert, and Yin Fangfang. Mon . "Radiotherapy Treatment Plans With RapidArc for Prostate Cancer Involving Seminal Vesicles and Lymph Nodes". United States. doi:10.1016/j.ijrobp.2009.07.1677.
@article{osti_21372121,
title = {Radiotherapy Treatment Plans With RapidArc for Prostate Cancer Involving Seminal Vesicles and Lymph Nodes},
author = {Yoo, Sua, E-mail: sua.yoo@duke.ed and Wu, Q. Jackie and Lee, W. Robert and Yin Fangfang},
abstractNote = {Purpose: Dosimetric results and treatment delivery efficiency of RapidArc plans to those of conventional intensity-modulated radiotherapy (IMRT) plans were compared using the Eclipse treatment planning system for high-risk prostate cancer. Materials and Methods: This study included 10 patients. The primary planning target volume (PTV{sub P}) contained prostate, seminal vesicles, and pelvic lymph nodes with a margin. The boost PTV (PTV{sub B}) contained prostate and seminal vesicles with a margin. The total prescription dose was 75.6 Gy (46.8 Gy to PTV{sub P} and an additional 28.8 Gy to PTV{sub B}; 1.8 Gy/fraction). Three plans were generated for each PTV: Multiple-field IMRT, one-arc RapidArc (1ARC), and two-arc RapidArc (2ARC). Results: In the primary IMRT with PTV{sub P}, average mean doses to bladder, rectum and small bowel were lower by 5.9%, 7.7% and 4.3%, respectively, than in the primary 1ARC and by 3.6%, 4.8% and 3.1%, respectively, than in the primary 2ARC. In the boost IMRT with PTV{sub B}, average mean doses to bladder and rectum were lower by 2.6% and 4.8% than with the boost 1ARC and were higher by 0.6% and 0.2% than with the boost 2ARC. Integral doses were 7% to 9% higher with RapidArc than with IMRT for both primary and boost plans. Treatment delivery time was reduced by 2-7 minutes using RapidArc. Conclusion: For PTVs including prostate, seminal vesicles, and lymph nodes, IMRT performed better in dose sparing for bladder, rectum, and small bowel than did RapidArc. For PTVs including prostate and seminal vesicles, RapidArc with two arcs provided plans comparable to those for IMRT. The treatment delivery is more efficient with RapidArc.},
doi = {10.1016/j.ijrobp.2009.07.1677},
journal = {International Journal of Radiation Oncology, Biology and Physics},
number = 3,
volume = 76,
place = {United States},
year = {Mon Mar 01 00:00:00 EST 2010},
month = {Mon Mar 01 00:00:00 EST 2010}
}